TY - JOUR
T1 - Efficacy of paclitaxel/dexamethasone intra-tumoral delivery in treating orthotopic mouse breast cancer
AU - Popilski, Hen
AU - Abtew, Esther
AU - Schwendeman, Steven
AU - Domb, Abraham
AU - Stepensky, David
N1 - Funding Information:
This work was supported by the research grant No 2013/131 from the United States-Israel Binational Science Foundation .
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/6/10
Y1 - 2018/6/10
N2 - The effect of topical co-administration of promoter drugs with paclitaxel to increase anti-tumor effects of paclitaxel was investigated. Mice with orthotopic 4T1-Luc breast cancer received single intra-tumoral injection of a polymeric formulation with paclitaxel and a specific promoter drug. Several promoter drugs were evaluated, including: dexamethasone, losartan, nicotinamide, Azone, and oleic acid. Dexamethasone exhibited the highest effect on paclitaxel anti-tumor activity, in a dose-dependent fashion. However, this effect was accompanied by systemic effects of dexamethasone, and inability to prevent tumor metastasis to the lungs. Topical co-administration of promoter drugs with anti-cancer agents can enhance their anti-tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti-cancer drugs, and their suitability for the clinical management of the breast cancer disease.
AB - The effect of topical co-administration of promoter drugs with paclitaxel to increase anti-tumor effects of paclitaxel was investigated. Mice with orthotopic 4T1-Luc breast cancer received single intra-tumoral injection of a polymeric formulation with paclitaxel and a specific promoter drug. Several promoter drugs were evaluated, including: dexamethasone, losartan, nicotinamide, Azone, and oleic acid. Dexamethasone exhibited the highest effect on paclitaxel anti-tumor activity, in a dose-dependent fashion. However, this effect was accompanied by systemic effects of dexamethasone, and inability to prevent tumor metastasis to the lungs. Topical co-administration of promoter drugs with anti-cancer agents can enhance their anti-tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti-cancer drugs, and their suitability for the clinical management of the breast cancer disease.
KW - Dexamethasone
KW - Intra-tumoral implant
KW - Local anti-cancer treatment
KW - Orthotopic model of breast cancer
KW - Paclitaxel
KW - Promoter drugs
UR - http://www.scopus.com/inward/record.url?scp=85045469438&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2018.04.010
DO - 10.1016/j.jconrel.2018.04.010
M3 - Article
AN - SCOPUS:85045469438
SN - 0168-3659
VL - 279
SP - 1
EP - 7
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -
